
1 Title: Heparin Does Not Regulate Circulating Human PCSK9

- Authors: Vivian Q. Xia^{1,2}, Chui Mei Ong^{3,4}, Lucas S. Zier^{1,2}, John S. MacGregor^{1,2}, Alan H. B. 3
- 4 Wu^{3,4}, John S. Chorba*,1,2
- 5
- 6 Affiliations:
- 7 ¹Division of Cardiology, Zuckerberg San Francisco General Hospital
- 8 ²Department of Medicine, University of California San Francisco
- 9 ³Clinical Chemistry Laboratory, Zuckerberg San Francisco General Hospital
- 10 ⁴Department of Laboratory Medicine, University of California San Francisco
- 11
- 12 * Correspondence to: john.chorba@ucsf.edu
- 13
- 14 Abstract
- 15 Background: PCSK9 chaperones the hepatic low-density lipoprotein receptor (LDLR) for
- 16 lysosomal degradation, elevating serum LDL cholesterol and increasing the risk of
- 17 atherosclerotic heart disease. Though the major effect on the hepatic LDLR comes from
- 18 secreted PCSK9, the details of PCSK9 reuptake into the hepatocyte remain unclear. In both
- 19 tissue culture and animal models, heparan sulfate proteoglycans (HSPGs) on hepatocytes act
- 20 as co-receptors to promote PCSK9 reuptake. We hypothesized that if this PCSK9:HSPG
- 21 interaction is important in humans, disrupting the interaction with unfractionated heparin (UFH)
- 22 would acutely displace PCSK9 from the liver and increase plasma PCSK9.
- 23 Methods: We obtained remnant plasma samples from 160 subjects undergoing cardiac
- 24 catheterization before and after administration of intravenous UFH. PCSK9 levels were
- 25 determined using a commercial ELISA.

- 26 *Results:* Median plasma PCSK9 concentrations were 113 ng/ml prior to UFH and 119 ng/ml
- afterwards. This difference was not significantly different (p = 0.83, 95% CI of difference: -6.23
- to 6.31 ng/ml). Tests for equivalence provided 95% confidence that UFH administration would
- 29 not raise PCSK9 levels by more than 4.7% of the baseline value. No predefined subgroups
- 30 exhibited an effect of UFH on circulating PCSK9.
- 31 *Conclusion:* Administration of UFH does not result in a clinically meaningful effect on circulating
- 32 PCSK9 in humans. These results suggest that disruption of the PCSK9:HSPG interaction does
- 33 not affect PCSK9 reuptake into the liver. Further, they cast doubt on the clinical utility of
- 34 disrupting the PCSK9:HSPG interaction as a therapeutic strategy for PCSK9 inhibition.
- 35

36 Graphical Abstract

37



38

39

41 <u>Clinical Perspective</u>

42			
43	What is new?		
44	Prior tissue culture and animal data suggest that PCSK9 interacts with hepatic heparan		
45	sulfate proteoglycans to enter the liver and raise cholesterol levels		
46	• We found no evidence that heparin, a competitive inhibitor of heparan sulfate		
47	proteoglycans, acutely affects PCSK9 in humans		
48			
49	What are the clinical implications?		
50	Heparin is unlikely to be successfully repurposed as a PCSK9 inhibitor		
51			
52	<u>Main Text</u>		
53			
54	PCSK9 chaperones the hepatic low-density lipoprotein receptor (LDLR) for lysosomal		
55	degradation, elevating serum LDL cholesterol and increasing the risk of atherosclerotic heart		
56	disease ¹ . Though the major effect on the hepatic LDLR comes from secreted PCSK9 ² , the		
57	details of PCSK9 reuptake into the hepatocyte remain unclear. In both tissue culture and animal		
58	models, heparan sulfate proteoglycans (HSPGs) on hepatocytes bind to an arginine-rich region		
59	on the PCSK9 prodomain to promote PCSK9 reuptake ^{3,4} . However, to date, the PCSK9:HSPG		
60	interaction has not been directly evaluated in humans. We hypothesized that if this interaction is		
61	important, disrupting it with unfractionated heparin (UFH) would acutely displace PCSK9 from		
62	the liver and increase plasma PCSK9. We therefore leveraged remnant blood samples from		
63	patients undergoing cardiac catheterization and short-term anticoagulation with intravenous (IV)		
64	UFH in the <u>Hep</u> arin <u>Block</u> ade of PCSK <u>9</u> ("HepBlock9") study (Fig. 1A). To our surprise, we		
65	observed no difference in circulating PCSK9 after UFH administration, suggesting that heparin		

66 is unlikely to be successfully repurposed for PCSK9 inhibition.

67

68	In a protocol approved with a waiver of informed consent by the Institutional Review Board of
69	the University of California, San Francisco (UCSF, CHR #18-26734), we targeted a sample size
70	of 150 subjects for 80% power at α = 0.05 (two-tailed) to detect a 4 ng/ml (7%) change in
71	PCSK9 ⁵ . This was a conservative calculation given the 25% reduction in PCSK9 observed upon
72	PCSK9:HSPG disruption in animal models ³ . We then collected 180 paired pre- and post-UFH
73	remnant plasma samples, excluding 20 subjects for unclear records of UFH administration, a
74	prolonged (> 8 hr) delay in sample collection, recent heparin use, or evidence of impaired liver
75	function. This left us with 160 subjects available for analysis, who represented a predominantly
76	male (69%) but ethnically diverse cohort (74% non-White) with the expected high prevalence of
77	atherosclerosis (74%), statin use (70%), and obstructive coronary disease (40%).
78	
79	We then measured plasma PCSK9 concentrations using a commercial ELISA (Abcam)
80	compatible with our collection strategy and reviewed the associated medical records. Median
81	PCSK9 concentrations were 113 ng/ml prior to UFH and 119 ng/ml after, with no significant
82	difference between the matched samples ($p = 0.83$, Fig. 1B&C). Equivalence testing provided
83	95% confidence that the rise in PCSK9 from UFH was no more than 5.35 ng/ml, or 4.7% of the
84	baseline. Because several homeostatic mechanisms regulate circulating PCSK9 ⁵ , we also
85	evaluated the effect of IV UFH on circulating PCSK9 after stratifying by sex, age, race, ethnicity,
86	burden of atherosclerosis, presentation of acute coronary syndrome (ACS), statin use, non-HDL
87	cholesterol, renal function, and UFH dose. However, we failed to identify any subgroup that
88	displayed a significant response (Fig. 1D). We conclude from these data that administration of
89	IV UFH does not raise PCSK9 concentrations acutely.
90	

We focused on bolus administration of UFH because the reported half-life of circulating PCSK9
is only 5 minutes². To assess whether longer UFH treatments are required to disrupt PCSK9

93 uptake, we compared baseline PCSK9 concentrations in our main cohort to the 12 subjects 94 excluded because of prior treatment with heparin-like products, but found no significant 95 difference (p = 0.24, Fig. 1E&F). We also measured PCSK9 concentrations in 22 separate 96 patients anticoagulated with continuous IV UFH. Median PCSK9 concentrations in the paired 97 samples were no different after either a 6 hr (p > 0.99, Fig. 1G) or 24 hr infusion (p = 0.55, Fig. 98 1G). Because this cohort displayed a wide distribution of baseline PCSK9 concentrations, we 99 also explored the effects on the fractional change in PCSK9 at both timepoints, but again found 100 no significant difference (p = 0.97 for 6 hrs. p = 0.18 for 24 hrs. Fig. 1H).


101

102 Together, our data support the null hypothesis: that administration of therapeutic UFH does not 103 disrupt PCSK9 reuptake or affect circulating PCSK9 concentrations. Our results highlight the 104 importance of assessing physiologic questions in humans to assess their clinical relevance, 105 given the observations on the PCSK9:HSPG interaction in prior models^{3,4}. The strengths of our 106 study include 1) direct measurements in human subjects, without need for an experimental 107 animal model, 2) the clinical relevance to potential drug repurposing, even if the answer is 108 negative, 3) temporal observations to draw causal inferences, 4) the diverse ethnic population of 109 our sample, improving the generalizability of our findings, and 5) the use of subjects as their 110 own controls to minimize confounding from the substantial variability in PCSK9 concentrations 111 among individuals. Our study is limited by 1) a reliance on static measurements, leaving us 112 unable to directly assess PCSK9 kinetics or shifts between body compartments, 2) a sample 113 size powered for our main hypothesis but not necessarily subgroup analyses, and 3) the focus 114 on acute UFH administration, which limits our conclusions regarding long-term HSPG blockade. 115 Given the relative infrequency of PCSK9 variants, we also cannot comment on the role of the 116 PCSK9:HSPG interaction in certain genetic backgrounds, which may yet remain important⁴.

117

118	In conclusion, we found no evidence that heparin acutely interferes with PCSK9 uptake, casting				
119	doubt on the clinical utility of disrupting the PCSK9:HSPG interaction as a potential strategy to				
120	inhibit PCSK9 function.				
121					
122					
123	Acknowledgments: We thank the UCSF cardiology fellows and nursing staff of the ZSFG				
124	cardiac catheterization laboratory for preservation of remnant samples.				
125					
126	Funding: This work was supported by the NIH/NHLBI (K08 HL124068, R03 HL145259, R01				
127	HL146404, and R01 HL159457), a Pfizer ASPIRE Cardiovascular Award, the Harris Fund, the				
128	Research Evaluation and Allocation Committee of the UCSF School of Medicine, all to J.S.C.				
129					
130	Author contributions: Overall study design: J.S.C; Supervision of preservation of remnant				
131	samples: L.S.Z, J.S.M.; Storage and processing of remnant samples: C.M.O, A.H.B.W.;				
132	Determination of PCSK9 concentrations: V.Q.X, J.S.C; Data analysis: V.Q.X, J.S.C; Manuscript				
133	preparation: J.S.C; Critical review and revision of the manuscript: All authors.				
134					
135	Competing interests: J.S.C. has received consulting fees from Gilde Healthcare and Eko.				
136					
137	Data availability: Additional data and materials requests are available from the corresponding				
138	author via material transfer agreement, subject to IRB review.				
139					
140					
141	References				
142					
143	1. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: A Key Modulator of Cardiovascular				

144		Health. Circ Res. 2014;114(6):1022-1036. doi:10.1161/CIRCRESAHA.114.301621
145	2.	Grefhorst A, McNutt MC, Lagace TA, Horton JD. Plasma PCSK9 preferentially reduces
146		liver LDL receptors in mice. J Lipid Res. 2008. doi:10.1194/jlr.M800027-JLR200
147	3.	Gustafsen C, Olsen D, Vilstrup J, et al. Heparan sulfate proteoglycans present PCSK9 to
148		the LDL receptor. Nat Commun. 2017;8(1):503. doi:10.1038/s41467-017-00568-7
149	4.	Galvan AM, Chorba JS. Cell-associated heparin-like molecules modulate the ability of
150		LDL to regulate PCSK9 uptake. <i>J Lipid Res</i> . 2019;60(1):71-84. doi:10.1194/jlr.M087189
151	5.	Lakoski SG, Lagace T a, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic
152		determinants of plasma PCSK9 levels. J Clin Endocrinol Metab. 2009;94(7):2537-2543.
153		doi:10.1210/jc.2009-0141
154		
155		
156		
157		
158		



159

Figure 1: HepBlock9 Study. *A*) Schematic of study. Remnant blood samples before and after
 heparin administration in subjects undergoing cardiac catheterization were tested for PCSK9
 concentrations. *B*) Plasma PCSK9 concentrations in study subjects before (black) and after

164 (pink) IV UFH administration. C) Difference in plasma PCSK9 concentrations before and after IV 165 UFH in total subjects. Source data is the same as from B. D) Difference in plasma PCSK9 166 concentrations before and after IV UFH in subjects stratified by sex, age, race, ethnicity, 167 obstructive CAD, atherosclerosis, ACS presentation, percutaneous coronary intervention (PCI), 168 statin use, serum non-HDL cholesterol, serum creatinine, or heparin dose, E) Baseline (pre-169 UFH) plasma PCSK9 concentrations in study subjects (after exclusions, black) and subjects 170 excluded due to prior UFH or low-molecular-weight heparin (LMWH) administration (purple). 171 Mann-Whitney test shown. F) Difference in PCSK9 concentrations before and after IV UFH in 172 subjects excluded due to prior UFH or LMWH administration. G) Plasma PCSK9 concentrations 173 before (black) or after 6 (teal) or 24 (light blue) hr infusions of IV UFH. Note the discontinuous Y 174 axis. H) Fractional difference in plasma PCSK9 concentrations before and after IV UFH 175 infusions. Source data is the same as from G. All panels) Unless otherwise noted, Wilcoxon 176 signed-rank tests shown, comparing matched-pairs between groups or to a hypothetical median 177 of 0, with Holm-Sidak corrections for multiple hypothesis testing when appropriate. n = number 178 of subjects in each group, ns = non-significant at adjusted p > 0.05.